Sends patients home with a chest patch that records their heart for 14 days, then turns that recording into a paid medical report.
What this company is and how it runs — written from structure, not news.
iRhythm makes a small adhesive patch called Zio that a patient wears on their chest for up to 14 days, continuously recording their heartbeat so that doctors can catch irregular rhythms — like atrial fibrillation — that only show up occasionally and would be missed by a short office visit. Once the patch is returned, iRhythm's AI algorithms process millions of heartbeats per patient to separate real cardiac events from movement noise, and the output is a clinical report that Medicare reimburses as a completed diagnostic procedure, which is how the company gets paid. Those algorithms only improve as more patients wear the patch and their outcomes are confirmed afterward, so the training dataset grows at the pace of actual patient deployments rather than software investment — meaning a competitor cannot simply buy their way to equivalent accuracy. Cardiologists also build their diagnostic routines around the Zio report format and hospitals wire their billing systems to the specific Medicare codes tied to it, so switching to a different patch means retraining staff and rewiring workflows at the same time.
How does this company make money?
Each time a patient completes a monitoring cycle and a clinical report is delivered to the ordering physician, the company collects a per-procedure fee. Those fees come from Medicare, Medicaid, and commercial insurers, billed under ambulatory cardiac monitoring CPT codes. There is no subscription or hardware sale driving revenue — the money arrives one completed monitoring cycle at a time.
What makes this company hard to replace?
Cardiologists learn to read Zio report formats and build their diagnostic routines around them, and switching to a different system means retraining. Hospital billing departments configure their revenue cycle management systems around the specific Medicare billing codes tied to Zio monitoring. Patient referral workflows get built into electronic health record order sets that default to established ambulatory monitoring providers, making it operationally inconvenient to route patients elsewhere.
What limits this company?
The AI gets more accurate only as more patients wear the patch and their follow-up medical outcomes get confirmed and added to the training dataset. That process runs at the biological pace of real patient care — it cannot be sped up by spending more money or hiring more software engineers.
What does this company depend on?
The company cannot operate without FDA 510(k) clearance for the Zio patch device, CE marking for European sales, Medicare reimbursement codes for long-term continuous monitoring, proprietary adhesive materials that keep the patch on skin for 14 days, and cloud computing infrastructure to process terabytes of ECG data.
Who depends on this company?
Cardiologists lose access to wire-free extended monitoring for catching paroxysmal atrial fibrillation that brief office visits miss. Primary care physicians lose a direct way to investigate patient-reported palpitations without routing everyone through specialist-controlled Holter monitoring. Medicare patients lose coverage for a comfortable home-based option that traditional wired devices cannot replace because patients simply take those off.
How does this company scale?
As more patients generate ECG data, the AI algorithms improve automatically, which reduces the cost and effort of analyzing each new recording — that part scales well. But physically manufacturing patches and having clinical technicians review algorithm outputs cannot be fully automated, so those two steps remain labor-intensive and grow roughly in line with patient volume rather than ahead of it.
What external forces can significantly affect this company?
Medicare reimbursement rate changes for ambulatory cardiac monitoring directly affect how much the company earns per procedure and whether physicians bother ordering it. FDA guidance on AI-based diagnostic tools could require expensive revalidation studies at any time. An aging population means more people developing atrial fibrillation, which grows the addressable market, but also puts pressure on healthcare budgets that pay for these procedures.
Where is this company structurally vulnerable?
If a larger medical device company deployed a comparable wire-free patch at scale across its existing patient base, it could begin accumulating the same kind of annotated dataset and eventually close the accuracy gap. Separately, if the FDA required full revalidation of AI-based diagnostic algorithms against a new clinical standard, the years of accumulated annotation would need to be re-certified, breaking the direct link between historical deployment volume and current diagnostic approval.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Two structural conditions align: (1) a multi-year price band exists where the stock has, on at least two separated occasions, stopped declining and bounced upward, and (2) current price is back inside or just above that zone after a meaningful drawdown from peak. The retest is a real one — the stock is not at a new all-time high being measured as a low.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Three leverage observations have converged at elevated readings: debt is large relative to equity, large relative to total assets, and large relative to trailing operating cash flow. The capital structure is leveraged on three different denominators at once.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph